GenSight Biologics to Attend Chardan Gene Therapy Conference
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will attend the following investor conference: Chardan Inaugural Gene Therapy ConferenceTuesday, October 10, 2017 – New York (USA)Thomas Gidoin, Chief Financia